公开(公告)号：US20230157581A1

公开(公告)日：2023-05-25

申请号：US17533479

申请日：2021-11-23

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE PARIS ,  MUSEUM NATIONAL D'HISTOIRE NATURELLE ,  SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  SORBONNE UNIVERSITE ,  UNIVERSITE DE PARIS-SACLAY

Inventor： Christophe Goupil ,  Philippe Lecoeur ,  Vincent BELS ,  Eric HERBERT ,  Henni OUERDANE

IPC: A61B5/11 ,  G16H20/30 ,  A61B5/0205

CPC classification number: A61B5/1118 ,  G16H20/30 ,  A61B5/0205

Abstract: The present invention relates to a method of determining metabolic parameters of one or several muscular motor units by coupling muscular response to ventilatory response of a subject, comprising, from a step of performing efforts (i) using a test device by the subject moving on the test device; (ii)-a step of instantaneously measuring the movement speed of one or several muscular motor units of the subject v(t), and the oxygen flow rate φO2t); (iii)-a step of plotting the COT curve of the oxygen flow rate of the subject against the movement speed of one or several muscular motor units of the subject v(t), (iv)-a step of determining the following metabolic parameters from the COT curve: Basal power B which is the vertical asymptote at the origin, Flow resistance RM which is the oblique asymptote at high intensities.

公开(公告)号：US20210268056A1

公开(公告)日：2021-09-02

申请号：US17257274

申请日：2019-07-03

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  UNIVERSITE MONTPELLIER III PAUL VALERY ,  INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT ,  FLORE EN THYM

Inventor： Nathalie Saint ,  Sylvie Rapior ,  Manon Vitou ,  Guillaume Bouguet ,  Gilles Carnac ,  Sylvie Morel

IPC: A61K36/537 ,  A61K31/122 ,  A23K20/111 ,  A23K20/158

Abstract: The present invention relates to the abietane diterpene taxodione and to rosemary stem extract containing taxodione for their use in treating a muscle wasting diseases and/or disorders; it also relates to the use of taxodione as natural meat preserver.

公开(公告)号：US20240228987A1

公开(公告)日：2024-07-11

申请号：US18563078

申请日：2022-05-25

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE MONTPELLIER ,  UNIVERSITE DE PERPIGNAN VIA DOMITIA ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Nicolas TRICAUD ,  Nicolas INGUIMBERT ,  Benoît GAUTIER

IPC: C12N9/12 ,  A61K38/00 ,  A61P25/28

CPC classification number: C12N9/1205 ,  A61P25/28 ,  A61K38/00 ,  C12Y207/01001

Abstract: The inventors previously demonstrated that mitochondrial VDAC1 directly induces Schwann cell demyelination via MAPK and c-jun activation after sciatic nerve injury and diabetic neuropathy and CMT1A. They found that reduction of mitochondrial calcium release by VDAC1 blocking strongly reduces the number of demyelinating Schwann cell in vivo and improve nerve conduction and neuromuscular activity in diabetic, Guillain-Barre syndrome and Charcot-Marie Tooth disease models. Herein, the inventors precisely map the binding region of the N-terminal HK-1 helix through an ala scan completed by a deletion study. Furthermore, they optimized the HK-derived peptide through stabilization of the helix by replacement of non-essential amino acids by the a-aminoisobutyric acid (Aib) known as a helix inducer. Additionally, they described an in-house cellular screening assay based on the ability of MJ to detach HK from VDAC that allows to determine the peptide potency. Overall, their data confirm that N-terminal HK derived peptides acting on VDAC are promising tools for the study of the demyelination process. Thus, the present invention refers to optimized HK-derived peptide and its use for treating peripheral demyelinating disease, myocardium diseases10 11, cancer12,13-15, diabetes14 14-16, lupus-like diseases17, non-alcoholic fatty liver disease24,25, chemoinduced neuropathy9 Alzheimer disease18 19, Parkinson disease20, Huntington disease21, ALS22,23 and more generally all neurodegenerative diseases linked to a protein aggregation28.

公开(公告)号：US20230270695A1

公开(公告)日：2023-08-31

申请号：US17924420

申请日：2021-05-20

Applicant: REST THERAPEUTICS ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  ECOLE PRATIQUE DES HAUTES ETUDES

Inventor： Gilles RUBINSTENN ,  Tangui MAURICE

IPC: A61K31/136 ,  A61P39/06

CPC classification number: A61K31/136 ,  A61P39/06

Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in inducing neuroprotection, in a subject in need thereof. The compound or a pharmaceutically acceptable salt thereof can be used in inducing neuroprotection in a subject suffering from, suspected of suffering from, or considered to be at risk of suffering from a neurodegenerative pathology. The compound or a pharmaceutically acceptable salt thereof also can be used in preventing or treating a neurodegenerative pathology, and/or in preventing or decreasing cognitive impairment in a subject suffering from, suspected of suffering from, or considered to be at risk of suffering from a neurodegenerative pathology.

公开(公告)号：US20180206447A1

公开(公告)日：2018-07-26

申请号：US15746343

申请日：2016-07-22

Applicant: UNIVERSITE DE MONTPELLIER ,  INSERM-INSTITUT NATONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  ECOLE PRATIQUE DES HAUTES ETUDES

Inventor： Tangui MAURICE

IPC: A01K1/03 ,  A01K15/02 ,  A01K29/00 ,  A01K7/06 ,  A01K5/02 ,  A61B5/11 ,  A61B5/00

CPC classification number: A01K1/031 ,  A01K5/0233 ,  A01K7/06 ,  A01K15/02 ,  A01K15/027 ,  A01K29/005 ,  A61B5/1105 ,  A61B5/1113 ,  A61B5/1122 ,  A61B5/165 ,  A61B5/4088 ,  A61B2503/40 ,  A61B2503/42

Abstract: A device is provided for studying the ability of at least one mouse to find its bearings in a maze, the device including a plurality of houses distributed around a central agora and in which at least one stimulator allows the at least one mouse to carry out certain activities and/or satisfy certain primary needs. Each house further includes at least one sensor for measuring the activity of the mouse in the house, and more particularly its use of the at least one stimulator. Finally, a sensor makes it possible to detect and measure the movements of each mouse in the device. Quantitative parameters originating from these measurements thus make it possible to highlight the quality of the geographical memory of the at least one mouse.

公开(公告)号：US20220062228A1

公开(公告)日：2022-03-03

申请号：US17415084

申请日：2019-12-19

Applicant: Centre National De La Recherche Scientifique ,  Universite De Montpellier ,  Institut National De La Sante Et De La Recherche Medicale (INSERM) ,  Universite Paul-Valery Montpellier 3 ,  Ecole Pratique Des Hautes Etudes (EPHE) ,  Institut De Recherche Pour Le Developpement

Inventor： Gilles CARNAC ,  Nathalie SAINT ,  Sylvie MOREL ,  Sylvie RAPIOR ,  Manon VITOU

IPC: A61K31/366 ,  A61P21/06

Abstract: The present invention relates to the use of carnosol or of a composition comprising carnosol for increasing muscle protein synthesis and/or for reducing the muscle protein degradation in a subject.

公开(公告)号：US20190144476A1

公开(公告)日：2019-05-16

申请号：US16097914

申请日：2017-04-27

Applicant: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM) ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ DE MONTPELLIER

Inventor： Tangui MAURICE ,  Jean-Noël VOLLE ,  David VIRIEUX ,  Jean-Luc PIRAT ,  Coralie LABORDE

IPC: C07F9/6584 ,  A61P25/28

Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R′ is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.

公开(公告)号：US20180177915A1

公开(公告)日：2018-06-28

申请号：US15735992

申请日：2016-06-17

Applicant: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  COLLEGE DE FRANCE

Inventor： Nadine NASSIF ,  Marie-Madeleine GIRAUD-GUILLE ,  Yan WANG ,  Marc ROBIN ,  Flore SALVIAT

IPC: A61L27/24 ,  A61L27/50

CPC classification number: A61L27/24 ,  A61L27/50 ,  A61L2430/16 ,  A61L2430/34

Abstract: Disclosed is a method for preparing a transparent fibrillated collagen matrix capable of being used as a tissue substitute in the production of a tissue or an artificial organ, in particular for a cornea substitute.

公开(公告)号：US20250000818A1

公开(公告)日：2025-01-02

申请号：US18708355

申请日：2022-11-08

Applicant: REST Therapeutics ,  Institut National de la Sante et de la recherche Medicale ,  UNIVERSITE DE MONTPELLIER ,  ECOLE PRATIQUE DES HAUTES ETUDES

Inventor： Gilles RUBINSTENN ,  Tangui MAURICE ,  Aline FREYSSIN

IPC: A61K31/13 ,  A61K31/445 ,  A61K45/06

Abstract: The invention relates to a composition comprising a synergistic combination of fluoroethylnormemantine (FENM) and at least one acetylcholinesterase inhibitor. More particularly, the invention relates to said composition for use thereof as a drug, even more particularly for use thereof in the treatment of a pathology selected from among tauopathies, synucleinopathies, amyloidopathies, Alzheimer's disease, Parkinson's disease, multiple system atrophy, Huntington's disease, posterior cortical atrophy, Pick's disease, epilepsy, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, amyotrophic lateral sclerosis.

公开(公告)号：US20230049619A1

公开(公告)日：2023-02-16

申请号：US17785939

申请日：2020-12-18

Applicant: UNIVERSITE DE STRASBOURG ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE DE MONTPELLIER ,  ECOLE PRATIQUE DES HAUTES ETUDES

Inventor： JEAN-JACQUES BOURGUIGNON ,  MARTINE SCHMITT ,  JACQUES BRICARD ,  TANGUI MAURICE

IPC: C07D403/04 ,  A61P25/00

Abstract: The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and multiple sclerosis.